Amgen has launched its Bkemv (eculizumab-aeeb) biosimilar to Alexion’s Soliris in the US, entering the market as the first interchangeable biosimilar to the brand under the terms of a settlement agreement struck with the originator back in 2020 that allowed market entry from 1 March.
Bkemv was approved by the US Food and Drug Administration in May 2024 in the same dosage form and strength as Soliris, and with the same route of administration and dosing regimen
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?